{
    "clinical_study": {
        "@rank": "92544", 
        "arm_group": {
            "arm_group_label": "Venus P-valve implantation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "A prospective, non-randomized, multi-center clinical study of the Venus P-valve for the\n      treatment of RVOT stenosis with pulmonary regurgitation after surgery of congenital heart\n      defect."
        }, 
        "brief_title": "Efficacy and Safety of Venus P-valve to Treat RVOT Stenosis With Pulmonary Regurgitation", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "RVOT Stenosis", 
        "condition_browse": {
            "mesh_term": [
                "Constriction, Pathologic", 
                "Heart Defects, Congenital", 
                "Pulmonary Valve Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "The aim of this protocol is to assess the efficacy, safety and performance of Venus P-valve.\n\n      Patients between 18-60 years with RVOT stenosis and moderate to severe pulmonary\n      regurgitation (\u22653+) who have undergone trans-annular patch repair of their RVOT, cardiac\n      magnetic resonance (CMR) screening right ventricular end-diastolic volume index (RVEDVI)\n      between 130-160mL/m2.\n\n      Post-procedure follow-ups will be scheduled at 24 hours, 30 days, 6 months and 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  RVOT stenosis who have undergone transannular patch repair with moderate to severe\n             pulmonary regurgitation\n\n          -  Isotopic or CMR criteria of RVEDVI\u2265130mL/m2   and \u2264160mL/m2\n\n          -  Age\u226518 years and \u226460 years (Zhongshan Hospital age\u226518 years and \u226460 years\n\n          -  Body weight\u226518 kg\n\n          -  Pulmonary annular diameter between 14mm to 31mm\n\n          -  RVOT length\u226520mm\n\n          -  The subject or his/her legal representative has provided written informed consent\n\n          -  Subject will comply with protocol required follow-ups\n\n        Add any of the following conditions:\n\n          -  Subject is symptomatic\n\n          -  Subject presents with >30% pulmonary regurgitation fraction as defined by cardiac MRI\n\n          -  \u22653+ pulmonary regurgitation by echocardiograms\n\n          -  Deteriorating RVEF%\n\n          -  Progressive tricuspid valve regurgitation (at least moderate degree)\n\n          -  Complicated with RVOT obstruction (RV systolic pressure>80mmHg)\n\n          -  Persistent arrhythmias\n\n        Exclusion Criteria:\n\n        Candidates will be excluded from the study if any of the following conditions are present:\n\n          -  Existing pulmonary artery branch stenosis or artificial pulmonary valve\n\n          -  Severe chest wall deformity\n\n          -  ADHF\n\n          -  Active infection or endocarditis requiring antibiotic therapy\n\n          -  Leukopenia (WBC<3000mm3)\n\n          -  Acute or chronic anemia (Hb<9g/L)\n\n          -  Platelet account <100,000 cells/mm3\n\n          -  In the judgment of the investigator, percutaneous introduction and delivery of the\n             valve is not feasible\n\n          -  A known hypersensitivity to aspirin or heparin\n\n          -  Positive urine or serum pregnancy test in female subjects\n\n          -  Ileofemoral vessel characteristics that would preclude safe placement of introducer\n             sheath"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071654", 
            "org_study_id": "VEN2013-10/V2.0"
        }, 
        "intervention": {
            "arm_group_label": "Venus P-valve implantation", 
            "intervention_name": "Venus P-valve transcatheter implantation", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Venus P-valve", 
        "lastchanged_date": "March 16, 2014", 
        "location": {
            "contact": {
                "email": "davidliu@coremed.com.cn", 
                "last_name": "David Liu, MD", 
                "phone": "+86 10 6595 6828", 
                "phone_ext": "806"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Zhongshan Hospital Fudan University"
            }, 
            "investigator": {
                "last_name": "Daxin Zhou, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficacy and Safety Evaluation of Transcatheter Pulmonary Valve Implantation for Right Ventricular Outflow Tract (RVOT) Stenosis After Congenital Heart Defect Surgical Correction Complicated With Severe Pulmonary Regurgitation", 
        "other_outcome": [
            {
                "description": "Immediate success of implantation of the device measured in percentage (placement of the device and functional stability measured with angiography and hemodynamic performance).\nFunction normal of the P valve measured in percentage without major adverse events at day 7.\n(Function normal defined as the P valve's position and function are normal through exams of electrocardiography (EKG), transthoracic echocardiogram (TTE), chest X-ray. )", 
                "measure": "Feasibility and Performance Endpoints", 
                "safety_issue": "No", 
                "time_frame": "Day 7 post-implantation"
            }, 
            {
                "description": "Changes of images and clinical parameters pre- and post-procedure at 12 months.\nCMR: right ventricular volume (expressed as ml/m2), RV ejection fraction (expressed as percentage), pulmonary regurgitation (functional classification as grade I, IIa, IIb and III).\nEcho: device position(expressed as percentage), hemodynamic performance of velocity of RVOT and pulmonary valve (expressed as m/s), transvalvular pressure gradient, peak pulmonary valve gradient, mean gradient (expressed as the difference of pressure in mmHg.)\nNYHA class", 
                "measure": "Secondary Endpoints", 
                "safety_issue": "No", 
                "time_frame": "From the date of valve implantation till 12 months post-procedure"
            }
        ], 
        "overall_contact": {
            "email": "davidliu@coremed.com.cn", 
            "last_name": "David Liu, MD", 
            "phone": "+86 10 6595 6828", 
            "phone_ext": "806"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Junbo Ge, Prof., MD.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The improvement is defined as the RVEDVI\u2264108mL/m2 measured with CMR.", 
            "measure": "Improvement rate of RVEDV at 6 months post-procedure.", 
            "safety_issue": "No", 
            "time_frame": "At 6 months post-implantation of Venus-P valve"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071654"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Accumulated occurrences (rate of patients/year) of procedure-related clinical events (death, severe arrhythmias, cardiac tamponade, RVOT or pulmonary artery perforation or rupture, cardiac shock, endocarditis from the date of valve implantation up to 12 months post-procedure or  bleeding due to use of heparin/aspirin at 48 hours post-procedure assessed per protocol.\nOccurrence of all deaths (cardiac death, non-cardiac deaths and other deaths) and stroke one year post-procedure.", 
            "measure": "Safety Endpoints", 
            "safety_issue": "Yes", 
            "time_frame": "From the date of implantation until 12 months post-procedure"
        }, 
        "source": "Venus MedTech (HangZhou) Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Core Medical (Beijing) Co., Ltd.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Venus MedTech (HangZhou) Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}